Abstract Precise identiWcation of regulatory T cells is crucial in the understanding of their role in human cancers. Here, we analyzed the frequency and phenotype of regulatory T cells (Tregs), in both healthy donors and melanoma patients, based on the expression of the transcription factor FOXP3, which, to date, is the most reliable marker for Tregs, at least in mice. We observed that FOXP3 expression is not conWned to human CD25 +/high CD4 + T cells, and that these cells are not homogenously FOXP3 + . The circulating relative levels of FOXP3 + CD4 + T cells may Xuctuate close to 2-fold over a short period of observation and are signiWcantly higher in women than in men. Further, we showed that FOXP3 + CD4 + T cells are over-represented in peripheral blood of melanoma patients, as compared to healthy donors, and that they are even more enriched in tumor-inWltrated lymph nodes and at tumor sites, but not in normal lymph nodes. Interestingly, in melanoma patients, a signiWcantly higher proportion of functional, antigen-experienced FOXP3 + CD4 + T was observed at tumor sites, compared to peripheral blood. Together, our data suggest that local accumulation and diVerentiation of Tregs is, at least in part, tumor-driven, and illustrate a reliable combination of markers for their monitoring in various clinical settings.
Introduction
Accumulating evidence suggests that a thymus-derived population of natural regulatory T cells (Tregs) play a central role in controlling immune responsiveness to self-and allo-antigens [39] . CD4 + T cells constitutively expressing high levels of the IL-2 receptor chain (CD25) were found to be enriched for immunosuppressive activity. In mice, absence of these cells leads to early appearance of a combination of multiple autoimmune manifestations, culminating in a wasting disease. Adoptive transfer of animals with CD4 + CD25 + T cells inhibits the development of autoimmunity by suppressing self-reactive T cells in the periphery. Nevertheless, the value of CD25 as a biomarker for regulatory T cells is limited, particularly in humans, since it is also expressed on recently activated CD4 + and CD8 + T cells. FOXP3, a member of the FOXP family of transcription factors (FOXP1-4), has recently been discovered as a major marker and functional regulator of Treg cell development. This Wnding brought out the possibility for a better characterization of Tregs in both mouse and humans [16, 47, 51] . Mutations in the foxp3 gene were linked to autoimmune manifestations observed in the Scurfy mouse [9] and in humans with the IPEX syndrome, a lethal X-linked disease characterized by immune deregulation, polyendocrinopathy, and enteropathy [6, 8] . Transfection of FOXP3 in CD4 + CD25 ¡ naive T cells can convert them to functionally and phenotypically natural Treg-like cells [22] . Moreover, a recent report on the function of IL-2 in foxp3-expressing cells showed that foxp3 + CD4 + T cells normally develop in IL2¡/¡ and IL2R ¡/¡ mice, and are fully able to suppress T cell proliferation in vitro [15] . Recent observations suggest that FOXP3 cooperates with NFAT, and physical interaction between these two molecules switches the activation program of a T cell into a suppressor program [50] . These results indicate that FOXP3 is a master control gene for the development and function of natural Treg. CD4 + T cells play an important, but dual role in regulating host immune responses against cancer. On one hand, the combined and concomitant activation of both helper CD4 + T cells and cytolytic CD8 + T cells greatly potentiate the eradication of tumor cells. On the other hand, the presence of CD4 + T cells displaying suppressive activity at the tumor site may play a signiWcant role in inhibiting antitumor immunity [25] .
In human cancer, a state of local immune tolerance, concerning both CD8 + T cell activation and function, has recently been reported [2, 21, 53] . Multiple mechanisms have been postulated for being responsible for preventing an eYcient anti-tumor response: from the tumor cell side, diVerent escape mechanisms have been described (e.g., down regulation of HLA molecules, loss of expression of tumor-associated antigens, secretion of inhibitory cytokines, lack of costimulatory molecules) [2, 18, 24] . From the immune cell side, the accumulation of lymphocytes with suppressive function could abrogate the anti-tumor cytotoxic response. An increased prevalence of CD25 + CD4 + T cells in peripheral blood or at tumor sites in patients bearing diVerent types of epithelial cancer suggest that these cells are Tregs inhibiting an eYcient antitumor cytotoxic response [11, 23, 28, 46, 49] . However, the majority of data available to date on FOXP3 + CD4 + T cells in human cancers mainly focused on their monitoring by immunohistochemical analysis in biopsy of tissue sections [4, 13, [29] [30] [31] 33] , with the consequent impossibility of a multiparametric monitoring, an exact quantiWcation of Tregs in diVerent body compartments, and an evaluation of their functionality. Flow cytometric detection of FOXP3 + CD4 + T cells at the single cell level has been illustrated in several recent human cancer reports, while the Xow cytometric Treg cell monitoring mainly relied on the evaluation of CD4 + CD25 + T cells [14, 20, 26, 42, 48] .
The purpose of our study was to directly characterize, by Xow cytometry, the population of FOXP3 + CD4 + T cells in humans, both in healthy donors (HDs) and melanoma patients.
Materials and methods

Tissues and cells
Peripheral blood (n = 42), metastatic lymph nodes (LNs) (tumor-inWltrated lymph nodes or TILN, n = 10), normal LNs diagnosed as tumor free by pathological examination (NLN, n = 10), and non-lymphoid tissue metastases (TIL, n = 3) were obtained from a total of 42 patients (stage III-IV, mean age: men 60.7, women 55.3 years). Informed consent was obtained from all patients (Lausanne University Hospital, Switzerland). Peripheral blood was obtained from healthy adult donors at the blood transfusion centre (Lausanne, Switzerland) (mean age: men 44.7, women 45.3 years). Cord blood samples were obtained from umbilical cord veins immediately after delivery of the placenta (University Hospital of Ghent, Belgium). Mononuclear cells were puriWed and immediately frozen as described previously [35] .
Antibodies and Xow cytometry
MAbs were from Becton Dickinson (San José, CA; antihuman CD25-PE, CD4-PECy7, CD127 puriWed, CD27-Alexa750, CD45RA-ECD, CCR7-puriWed, CTLA-4-APC or CTLA-4-PECy5, GAM-FITC, GAR-APC antibodies), except for anti-human-FOXP3-FITC (clone PCH 101) and CD127-paciWc blue antibodies (eBiosciences, San Diego, CA), and were used according to the manufacturer's recommendations. Thawed, cryopreserved PBMCs were stained in triplicates for healthy donors or monoplicates for melanoma patients. First, staining for cell surface markers was performed at 4°C. After wash, cells were Wxed, subsequently permeabilized with the eBiosciences Kit, and stained intracellularly for FOXP3.
Lymphocytes were gated according to their forward and side scatter characteristics, collected using a FACSCanto or LSRII, and analysis was performed using the CellQuest software (BD Biosciences, San José, CA).
Proliferation assay
Proliferation assays were performed using highly pure, Xow cytometry-based sorted CD4 + CD25 + CD127 ¡ and CD4 + CD25 ¡ CD127 + T cells, from PBLs of HDs (n = 4), PBLs from melanoma patients (n = 4), and from TILN of melanoma patients (n = 3). The gating strategy for sorting is shown in Fig. 4d 
Statistical analysis
The signiWcance of the results was determined using the Student t test. P values <0.05 were considered statistically signiWcant.
Results
FOXP3 and CD25 expression in human CD4
+ T cells in HDs and melanoma patients Lymphocytes from cord and peripheral blood of HDs as well as from peripheral blood, normal lymph nodes (NLNs), and TILNs from melanoma patients, were puriWed and stained with anti-CD4 and anti-CD25 antibodies and, once Wxed and permeabilized, with anti-FOXP3 antibody (Fig. 1a) . To establish the relationship between the two markers, electronically set gates according to increasing expression of CD25 were drawn on CD4 + T cells (Fig. 1b ) and percentages of FOXP3 + cells as well as mean Xuorescence intensity (MFI) values of FOXP3 expression were assessed in each subset (Fig. 1c, d, respectively) . While a signiWcant number of CD25 + cells expressed the FOXP3 marker, a proportion of FOXP3 + cells was clearly detectable in the CD25 intermediate and low subsets, as previously described for HDs [37] . For instance, in the NLN lymphocyte population, close to 50% of FOXP3 + CD4 + T cells expressed a CD25 low phenotype. For the same proportion of FOXP3 + CD4 + T cells, CD25 expression was greater in the PBL and TILN populations from a cancer patient, and even higher for cord blood and PBL of healthy donor origin. Thus, in samples from melanoma patients (both from peripheral blood and TILNs), high percentages of CD25 intermediate cells were positive for the FOXP3 marker. In contrast, an important proportion of the CD25 high cells (up to 30%) did not display any detectable FOXP3 expression, possibly corresponding to a population of recently activated T cells in the tumor-inWltrated tissues. FOXP3 MFI augments with increasing expression of CD25, in a similar manner in healthy donors (HDs) compared to patients. No detectable expression of FOXP3 on CD8 + T cells was observed by Xow cytometry, even if some of the cells were CD25 positive. No signiWcant staining was seen using an isotype matched control IgG-FITC (data not shown).
Treg kinetics in healthy donors' peripheral blood
Limited data are available to date on the frequency of FOXP3 + CD4 + T cells in cord blood and peripheral blood from HDs [17] . We found mean values of 3.5% (n = 4, range 1.6-6.2) and 2.9% (n = 53, range 1.1-5.7) of CD4 + T cells expressing the FOXP3 protein in cord and peripheral blood, respectively.
To compare results from HDs and patients, we Wrst conducted a study to assess the variation of FOXP3 + CD4 + T cell number in peripheral blood of HDs over time. In six HDs, three men and three women, the percentages of total CD4 + as well as FOXP3 + CD4 + T cells were monitored over a period of 2 months, with two additional late time points at 12 and 13 months. Overall percentages of total CD4 + T cells were stable over time in all individuals tested. Values ranged from 27.6 to 57.8% in the diVerent donors, with a mean coeYcient of variation (CV) over time of 6.9% (range 2.5-14.4) (data not shown).
Mean values of 2.4% (range 0.6-3.8) for men and 3.5% (range 2.4-7.6) for women of FOXP3 + cells in total CD4 + T cells were observed (Fig. 2a) + T cells in healthy donor (HD) blood. a Human lymphocytes puriWed from peripheral blood of HDs, three men (closed symbols) and three women (open symbols), were stained using a combination of anti-CD4 and anti-FOXP3 antibodies, in triplicates. Blood withdrawal was performed over a period of 13 months, on days 0, 2, 4, 11, 25, 53, 365, and 395. All the samples, from all time points, were frozen on the day of blood withdrawal, using the same standard operating procedure, and the staining was performed, in triplicates, on the same day for all the samples collected between days 0 and 4, between days 11 and 53, and 
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assessment of the expression of other markers (e.g., CD25, CD127, CTLA-4, CD27) on the FOXP3-positive population conWrmed that these cells display a typical Treg phenotype (e.g., CD127
¡ , CTLA-4 + , CD27 + ) (Fig. 2b) (Fig. 3) . Mean values of FOXP3 + T cells among total CD4 + T lymphocytes in HDs were 2.9% (range 1.1-5.7), compared to 5.05% (range 1.8-10.4) observed in melanoma patients. The diVerence was statistically signiWcant (P < 0.001), in contrast to data obtained in a previous report on CD4 + CD25 high T cells, where no statistically signiWcant diVerence was found on comparing the frequency of CD4 + CD25 high T cells in peripheral blood of HDs and melanoma patients [46] . SigniWcantly higher percentages of FOXP3 + CD4 + T cells were found in healthy women (mean of 3.7%) compared to healthy men (mean of 2.4%, P < 0.001); similarly, among melanoma patients, women showed higher percentages of FOXP3 + CD4 + T cells than men, with a mean of 5.5 and 4.5%, respectively. Yet, in the patients group, the observed diVerence did not reach statistical signiWcance.
Increased frequency of FOXP3
+ CD4 + T cells in TILNs and TILs of melanoma patients, compared to peripheral blood and normal LNs
We compared frequencies of FOXP3 + CD4 + T cells in ex vivo samples from four distinct body compartments: peripheral blood, NLNs, TILNs, and TILs ( Fig. 4a, b ; Table 1 ). Paired tissue samples were collected from a series of stage III/IV melanoma patients. The proportion of FOXP3 + CD4 + T cells was signiWcantly increased (P < 0.001) in the TILN (mean 17.4, range 9.1-28.3) compared to autologous PBLs (mean 6.9, range 3.7-13.0). An even higher increase was observed in TILs (mean 18.3, range 15.0-21.0, P < 0.001). In contrast, there was no statistical diVerence between frequencies of FOXP3 + CD4 + T cells in peripheral blood mononuclear cells and tumor-free LNs (P = 0.73), suggesting a selective increase of FOXP3 expressing CD4 + T cells in metastatic lesions (P < 0.001 when comparing NLNs vs. TILNs or NLNs vs. TILs) ( Fig. 4b; Table 1 ). Thus, FOXP3 + CD4 + T cells are increased in the tumor microenvironment of melanoma patients.
Phenotypic characterization in terms of CD25, CD127, CD27, and CTLA-4 of the identiWed FOXP3 + CD4 + T cells in the diVerent samples isolated from all the body compartments did not show any signiWcant diVerence. However, CTLA-4 expression was slightly increased in a proportion of TILN/TIL samples analyzed, yet not at a signiWcant level if compared to their peripheral blood counterpart (Fig. 4c) . Staining for LAP, mTGF , and GPR83 were negative in all the samples tested (data not shown).
From one particular patient, we had the opportunity to isolate at the same time point, lymphocytes from peripheral blood as well as from both a clinically progressing and a clinically regressing tumor-inWltrated lymph node. Interestingly, when assessing the percentage of FOXP3 + CD4 + T cells in these diVerent samples, we detected 5.9% in the peripheral blood, 13.7% in the progressing, while only 10.0% in the regressing lymph node.
Importantly, the detected Tregs, in both peripheral blood and tumor-inWltrated lymph nodes, displayed an eYcient (Fig. 4d) .
Increase of non-naive phenotype FOXP3 + CD4 + T cells in tumor-inWltrating lymph nodes, but not in normal LNs
Cord blood FOXP3 + CD4 + T cells predominantly display a naive phenotype, with the majority of the cells co-expressing Fig. 4 FOXP3 expression both CD45RA and CCR7 molecules on the cell surface (mean 57.8% of total FOXP3 + CD4 + T cells, data not shown). In the peripheral blood from HDs, on the contrary, CD4 + T cells that are positive for the FOXP3 marker are predominantly comprised of memory cells, with a proportion still being naïve (mean of 9.5% of naive cells in FOXP3 + CD4 + T cells, n = 37) (Fig. 5a, upper panel) . Phenotypic characterization of FOXP3 + CD4 + T cells in terms of CD45RA and CCR7 from PBLs, NLNs, and TILNs of melanoma patients revealed a signiWcant decrease in the CD45RA + CCR7 + FOXP3 + CD4 + T cells in TILNs compared to PBLs (Fig. 5a, middle and lower panels) . In contrast, comparison of percentages of naive and memory cells among the FOXP3 + T cells in PBLs and tumor-free LNs showed even higher levels of naive Treg cells in the lymph nodes. When the level of naive FOXP3 + CD4 + T cells in PBLs was arbitrarily deWned at 100%, a mean of 171 and 51% was observed in NLNs and TILNs, respectively (Fig. 5b) . In contrast, surprisingly, when comparing the total CD4 + T cell population, similar levels of naive cells were found in both tumor-free-and tumor-inWltratedlymph nodes, with 102 and 96%, respectively, if compared to peripheral blood (data not shown).
Discussion
The main Wnding in this paper is the accumulation of highly diVerentiated and functionally suppressive FOXP3 + CD4 + T cells in metastatic tumor lesions obtained from stage III to IV melanoma patients. First, we determined the correlation between CD25 and FOXP3 expression on human T cells in diVerent body compartments. While in cord as well as peripheral blood from both HDs and melanoma patients, expression of FOXP3 was, as expected, present in the majority of CD25-positive CD4 + T cells, a non-negligible proportion of CD25 expressing cells were FOXP3 negative in tumor lesions, indicating that, besides Tregs, eVector T lymphocytes up regulating the CD25 molecule are comprised in this population. Moreover, in CD25 int CD4 + T cells, we identiWed substantial numbers of FOXP3 expressing cells, while in CD25 low CD4 + T cells, only low but signiWcant percentages of cells were positive for FOXP3, similar to recent published data [27] . These observations correlate with some recent data generated in our laboratory on human CD4 + T cell clones. When CD4 + T cells were sorted by Xow cytometry according to their CD25 expression and cloned by limiting dilution, 60% of the CD25 + CD4 + sorted clones expressed FOXP3, while the remaining clones did not express the protein at a detectable level. The clones generated from CD25
¡ CD4 + sorted cells were 100% negative for FOXP3 (data not shown). Thus, together these data conWrm and extend the consensus view that comparability and relevance of data on Treg, deWned as CD25 + CD4 + T cells, are diYcult and questionable.
For the validation of FOXP3 antigen as a marker identifying Tregs by Xow cytometry and for their monitoring in clinical studies, it is important to know the consistency of the assay. In this regard, calculated inter-assay and intraassay CV were largely acceptable, being 6.9 and 9.7%, respectively. However, inter individual variations in FOXP3 + CD4 + T cells over time showed a mean CV of 35.3%, corresponding to an important Xuctuation of Tregs in HDs. The calculated 95% conWdential interval (CI) is 1.05-4.8% (mean § 1.96 SD). These important physiological variations in levels of FOXP3 + CD4 + T cells in HDs should be taken into account when interpreting past and future reports on the direct impact of diVerent clinical manipulations on Treg frequency [7, 12] . In light of the calculated 95% CI, we propose a threshold value of at least 1.8-fold increase/decrease, when comparing treatment-induced variations in Treg frequencies to be considered signiWcantly diVerent. Moreover, it should be kept in mind that signiWcant diVerences in Treg levels in the circulation are genderassociated. It might be possible that both observations, gender and time-dependent Xuctuations in Tregs levels, reXect regulation by steroid hormones. In this regard, it is very interesting that Xuctuations in the levels of Tregs have been very recently reported during the menstrual cycle [5] .
IdentiWed FOXP3 + CD4 + T cells also expressed high levels of the cytotoxic-T-lymphocyte associated antigen 4 (CTLA-4) and CD27, and were negative for CD127, correlating with previous observations [38, 41] . However,
FOXP3
+ cells did not detectably express some other old and new postulated speciWc Treg markers such as LAP, membrane bound TGFß or GPR83 (data not shown) [3, 32, 34, 43] . Other speciWc cell surface markers for characterizing naturally occurring Treg in humans are currently under investigation in our laboratory, including analyses at the T cell clonal level.
In melanoma, recent data from a cohort of patients revealed that tumor progression was correlated with increased levels of circulating CD25 + CD4 + T cells, and that a signiWcant clinical response to IL-2 therapy was only observed in those patients who displayed a decrease in CD25 + CD4 + T cells after treatment [10] . In a previous report on malignant melanoma, increased frequencies of CD25 + CD4 + T cells have been observed in TILN as compared to autologous PBLs, and their ability to inhibit the function of inWltrating T cells has been documented [46] . Similarly, in a patient suVering from melanoma with malignant ascites, despite a massive inXux of activated CD8 + T cells in the ascites Xuid, tumor progression was observed and CD25 + CD4 + T cells were increased in the ascites Xuid and inhibited the function of anti-tumor CD8 + T cells [21] . Since Treg frequency and function in these studies was mostly based on total CD25 + CD4 + T cells, while FOXP3 analysis relied on detection of the product by PCR, we re-examined this issue by speciWcally monitoring FOXP3 + CD4 + T cells by Xow cytometry, not only in peripheral blood, but also in tissues. Interestingly, a signiWcant increase of FOXP3 + CD4 + T cells was found in PBLs of patients compared to HDs. A recent report on eight metastatic melanoma or renal carcinoma patients [1] and three healthy donors also hinted at such a diVerence. An even higher prevalence of FOXP3 + CD4 + T cells was observed in our set of tumor-inWltrated tissues, while no diVerence was found in normal LNs, suggesting that the presence of tumor cells induced either the localized proliferation or the selective migration of FOXP3 + CD4 + T cells to tumor-inWltrated sites. One possible scenario could be that high levels of cytokines (e.g., IL-2, CCL22, TGF ) secreted by tumor cells possibly facilitate the attraction and local proliferation of FOXP3 + CD4 + T cells, as well as the in situ conversion of CD4 + T cells into Tregs [19, 45, 52, 54] . In this way, tumor cells could favor their growth through a selective expansion of Tregs. Further studies are necessary to dissect these hypotheses in detail.
In agreement with previously published data [17, 44] , we found a fraction of naive-phenotype Tregs in PBLs, in HDs, as well as in melanoma patients. Strikingly, we observed a selective decrease in the proportion of naive cells exclusively among FOXP3 + CD4 + T cells in TILN, and not among total CD4 + T cells. This observation points to tumor antigen-driven diVerentiation of FOXP3 + CD4 + T cells. This would imply that certain tumor-associated antigens can possibly inXuence the balance of helper and regulatory T cell proliferation, homing and diVerentiation, and thus support a selective enrichment of FOXP3 + CD4 + T cells. Finally, a parameter correlating with favorable clinical outcome and survival in cancer patients is the CD8 + /Treg cell ratio present in the tumor microenvironment [36, 40] . Interestingly, in the group of melanoma patients analyzed here, the highest CD8 + /FOXP3 + CD4 + T cell ratios were observed in two patients who showed the best clinical course (ratio of 13.3 and 10.9), while the remaining patients with progressing disease had clearly lower ratios (mean 1.8, range 0.5-3.5). A more accurate evaluation will only be possible once the ratio between CD8 + /FOXP3 + CD4 + T cells on antigen-speciWc level can be calculated. Still, our data suggest a possible role of Treg in anti-tumor immunity and the necessity of further characterizing them in terms of speciWc marker expression, mechanism of inhibition, and antigen speciWcity. Thus, novel cancer vaccine formulations aiming to favor the expansion of helper CD4 + T cells, and to limit Treg cell expansion, should be evaluated in conjunction with CD8 + T cells and at the level of antigenspeciWc immune responses. This may increase the chance to identify correlations with clinical responses, and ultimately achieve increased clinical eYcacy through immunotherapy.
